NONLIPID®

Composition
Each coated tablet contains: Rosuvastatin (as Rosuvastatin Calcium) 10 mg. Excipients q.s.

Therapeutic action
Lipid-lowering. Inhibitor of HMG-CoA reductase

Indications
Hyperlipidemia and mixed dyslipidemia
Rosuvastatin is indicated as adjuvant therapy to diet to reduce C – total, LDL-C, Apoẞ, non HDL-C and elevated triglycerides and to increase HDL-C in adult patients with primary Hyperlipidemia or Mixed Dyslipidemia. Agents for treating lipid alterations should be used in combination with a diet restricted in saturated fat and cholesterol, and when the response to diet and non-pharmacological interventions has been insufficient.
Pediatric patients 10 to 17 years of age with heterozygous Familial Hypercholesterolemia (HeFH):
Rosuvastatin is indicated as a dietary supplement to reduce total C, LDL-C, and Apoẞ levels in male and female adolescent who are at least 1 year after menarche, 10-17 years of age with heterozygous familial hypercholesterolemia if the following results are present after an appropriate diet test: LDL-C> 190 mg / dl or 160 mg / dl and there is a positive family history of premature cardiovascular disease (CVD) or two or more of other CVD risk factors.
Hypertriglyceridemia:
Rosuvastatin is indicated as a dietary adjuvant for the treatment of adult patients with hypertriglyceridemia.
Primary dysbetalipoproteinemia (Hyperlipoproteinemia type III):
Rosuvastatin is indicated as a dietary adjuvant for the treatment of patients with primary dysbetalipoproteinemia (type III hyperlipoproteinemia).
Homozygous familial hypercholesterolemia:
Rosuvastatin is indicated as adjuvant therapy to other lipid lowering treatments (eg LDL apheresis) or only if such treatments are not available to reduce LDL-C, C-total and Apoẞ in adult patients with homozygous familial hypercholesterolemia.
Delay on the progression of atherosclerosis:
Rosuvastatin is indicated as an adjuvant to diet to delay the progression of atherosclerosis in adult patients as part of a treatment strategy to reduce total C and LDL-C at target levels.
Primary prevention of cardiovascular events:
In adult patients with increased risk of cardiovascular disease, Arteriosclerotic, based on the presence of markers of risk for cardiovascular disease with a level of CRP ≥ 2, age (≥ 50 years in men and) ≥ 60 years for women), high blood pressure, HDL-C, smoking or a family history of premature coronary heart disease. Rosuvastatin is indicated to reduce the risk of stroke, arterial revascularization procedures and myocardial infarction.

Presentations 
Blister box containing 30 coated tablets.